Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The overall objective with the present study is to determine the long-term effects of docosahexaenoic acid (DHA) plus arachidonic acid (AA) supplementation on general cognitive ability, language, and executive function, and to examine genetic explanations for treatment effects, through one comprehensive study visit with children and parents from the Omega Tots trial cohort (NCT01576783).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previous participation in Omega Tots (NCT01576783).
- • Current age of 8 years, 180 days to 10 years, 180 days.
- Exclusion Criteria:
- • Child in custody of children's services for their window of eligibility
About Sarah Keim
Sarah Keim is a prominent clinical trial sponsor known for her commitment to advancing pediatric health research. With a robust background in epidemiology and a focus on improving health outcomes for children, she leads innovative studies that address critical gaps in understanding childhood diseases and treatments. Her collaborative approach fosters partnerships with academic institutions, healthcare organizations, and regulatory bodies, ensuring that research is conducted with the highest standards of ethics and scientific rigor. Through her leadership, Sarah Keim aims to contribute valuable insights that inform clinical practice and policy, ultimately enhancing the quality of care for pediatric populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Sarah Keim, PhD
Principal Investigator
Nationwide Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials